ingn 241
Gene therapyexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Mar 1, 2005 (NCT00116363)
Timeline
2000s
- Jan 1, 2005
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- Interleukin-24Supplementation
supplementation - MDA-7
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- ingn 241
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00116363 | Phase 2 | Mar 1, 2005 | Introgen Therapeutics, University of Texas at Houston |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Introgen Therapeutics | For profit | 1 | 1 | 1 | 2005 |
| University of Texas at Houston | Academic/Hospital | 1 | 0 | 1 | 2005 |
2 organizations
Page 1 / 1